Sensars Secures $1.4M to Revolutionize Diabetic Neuropathy Care with its Breakthrough SENSY System

Sensars is excited to announce a significant milestone in our journey toward revolutionizing care for diabetic neuropathy, having raised $1,400,000 in our latest funding round. This capital infusion represents not only investor confidence in our groundbreaking innovation, but also a commitment to improving the quality of life for millions affected by diabetic foot complications. As pioneers in neuromodulation for diabetic neuropathy, our flagship product SENSY is the first system designed to restore natural sensations to the feet, thereby reducing the risk of ulcers, amputations, falls, and chronic neuropathic pain. With this fresh funding, we are poised to advance our next phase of growth—moving from promising clinical studies toward pivotal trials and commercial readiness. Over the years, Sensars has built a robust foundation of clinical and academic success, evidenced by over 25 peer-reviewed publications, $3.5M secured in undiluted grants, and recognition from the FDA through breakthrough device designation. These achievements underscore both our scientific rigor and transformative approach to patient care. The newly raised capital will be strategically invested in scaling our clinical trials, fine-tuning our manufacturing capabilities, and expanding our market entry strategies to reach broader patient populations. Ultimately, our focus is to ensure that SENSY not only meets regulatory standards but also sets a new benchmark in diabetic foot care. We look forward to embarking on this next chapter with the unwavering support of our investors, partners, and the global medical community, as we strive to bring cutting-edge neuromodulation technology to those who need it most.